• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

475479-24-4 (Aleglitazar (racemate))

1

Identification

Aleglitazar (racemate) Aleglitazar (racemate)
Name Aleglitazar (racemate)
Formula C24H23NO5S
MW 437.5081
CAS No. 475479-24-4
EINECS
Smiles O=C(O)C(OC)CC1=C2C(C=CS2)=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C1
Synonyms
InChI InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)
2

Introduction

Background Information

Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ. ......by BOC Sciences
Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ) Target: PPARα/γ Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white solid EBNumber:EB000023025

Storage condition

Solubility

DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Aleglitazar (racemate) Hoffmann-La Roche Inc Cardiovascular disease 2012/12/31 2013/11/1 Phase 3 Clinical
Aleglitazar (racemate) Hoffmann-La Roche Inc Cardiovascular disease 2013/12/31 2019/1/31 Phase 3 Clinical
Aleglitazar (racemate) Hoffmann-La Roche Inc End stage renal disease 2013/12/31 2019/1/31 Phase 3 Clinical
Aleglitazar (racemate) Roche Holding AG Non-insulin dependent diabetes 2013/5/31 2013/8/31 Phase 3 Clinical
Aleglitazar (racemate) Roche Holding AG Non-insulin dependent diabetes 2013/6/30 2013/8/31 Phase 3 Clinical
Aleglitazar (racemate) Roche Holding AG Non-insulin dependent diabetes 2012/10/31 2013/8/31 Phase 3 Clinical
Aleglitazar (racemate) - Discontinued
Aleglitazar (racemate) - Phase 3
7

Safety Data of Aleglitazar (racemate)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Apexbio Technology LLC 5mg/USD287() USA
BOC Sciences
CHEMSCENE, LLC USA
Clearsynth Labs Limited 25mg/USD500() India
MedChemexpress Co., Ltd. 5mg/USD286(Get quote);10mg/USD369(Get quote);50mg/USD996(Get quote);100mg/USD1400(Get quote) USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD286(In stock);10mg/USD369(Get quote);50mg/USD996(Get quote);100mg/USD1400(Get quote) China
10

Related Products

Other Forms of 475479-24-4

Name CAS No Formula MW

Recommended Compounds in PPAR

Name CAS No Formula MW
(20S)-Protopanaxatriol 34080-08-5 C30H52O4 476.73
Procyanidin B2 29106-49-8 C30H26O12 578.52
Eupatilin 22368-21-4 C18H16O7 344.32
Fenofibric acid 42017-89-0 C17H15ClO4 318.75
Ciprofibrate 52214-84-3 C13H14Cl2O3 289.15
Bezafibrate 41859-67-0 C19H20ClNO4 361.82
Clofibrate 637-07-0 C12H15ClO3 242.7
Gemfibrozil 25812-30-0 C15H22O3 250.33
Pioglitazone 111025-46-8 C19H20N2O3S 356.44
GW0742 317318-84-6 C21H17F4NO3S2 471.4882
CDDO-Im 443104-02-7 C34H43N3O3 541.72
FH535 108409-83-2 C13H10Cl2N2O4S 361.2
Inolitazone (dihydrochloride) 223132-38-5 C27H28Cl2N4O4S 575.51
GW1929 196808-24-9 C30H29N3O4 495.57
Magnolol 528-43-8 C18H18O2 266.33
(±)-Naringenin 67604-48-2 C15H12O5 272.25
GSK3787 188591-46-0 C15H12ClF3N2O3S 392.78
Daidzein 486-66-8 C15H10O4 254.24
GW9662 22978-25-2 C13H9ClN2O3 276.68
Rosiglitazone 122320-73-4 C18H19N3O3S 357.43

Recommended Compounds in Same Indication

Name CAS No Formula MW
Glibenclamide 10238-21-8 C23H28ClN3O5S 494.0
Mitiglinide (Calcium) 145525-41-3 C38H50CaN2O7 686.89
Teneligliptin 760937-92-6 C22H30N6OS 426.58
Empagliflozin 864070-44-0 C23H27ClO7 450.91
MK 0893 870823-12-4 C32H27Cl2N3O4 588.48
Canagliflozin 842133-18-0 C24H25FO5S 444.52
Manidipine (dihydrochloride) 89226-75-5 C35H40Cl2N4O6 683.62
Teneligliptin (hydrobromide) 906093-29-6 C44H65Br5N12O2S2 1257.72
Exendin-4 (Acetate) 914454-01-6 C186H286N50O62S 4246.62
5-R-Rivaroxaban 865479-71-6 C19H18ClN3O5S 435.88
Trelagliptin 865759-25-7 C18H20FN5O2 357.38
Linagliptin 668270-12-0 C25H28N8O2 472.54
Bardoxolone 218600-44-3 C31H41NO4 491.66
Bardoxolone (methyl) 218600-53-4 C32H43NO4 505.69
Saxagliptin 361442-04-8 C18H25N3O2 315.41
Cinacalcet (hydrochloride) 364782-34-3 C22H23ClF3N 393.87
Rivaroxaban 366789-02-8 C19H18ClN3O5S 435.88
Alogliptin 850649-61-5 C18H21N5O2 339.39
Alogliptin (Benzoate) 850649-62-6 C25H27N5O4 461.51
Imeglimin (hydrochloride) 775351-61-6 C6H14ClN5 191.66
11

Route of Synthesis

12

References

13

More Information

Aleglitazar (racemate)

Tags: buy 475479-24-4 IC50 | 475479-24-4 price | 475479-24-4 cost | 475479-24-4 solubility | 475479-24-4 purchase | 475479-24-4 manufacturer | 475479-24-4 research buy | 475479-24-4 order | 475479-24-4 MSDS | 475479-24-4 chemical structure | 475479-24-4 Storage condition | 475479-24-4 molecular weight | 475479-24-4 mw | 475479-24-4 datasheet | 475479-24-4 supplier | 475479-24-4 cell line | 475479-24-4 NMR | 475479-24-4 MS | 475479-24-4 IR | 475479-24-4 solubility | 475479-24-4 Safe information | 475479-24-4 Qc and Spectral Information | 475479-24-4 Clinical Information | 475479-24-4 Clinical Trial | 475479-24-4 Route of Synthesis | 475479-24-4 storage condition | 475479-24-4 diseases and conditions | 475479-24-4 flash point | 475479-24-4 boiling point | 475479-24-4 melting point | 475479-24-4 storage condition | 475479-24-4 brand